Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent
- 29 July 2003
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (18) , 3091-3095
- https://doi.org/10.1016/s0960-894x(03)00654-1
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Restenosis Following Angioplasty in the Swine Coronary Artery Is Inhibited By an Orally Active PDGF-Receptor Tyrosine Kinase Inhibitor, RPR101511ACirculation, 1999
- Small molecule inhibitors of receptor tyrosine kinasesDrugs of the Future, 1999
- Potent Noncovalent Thrombin Inhibitors That Utilize the Unique Amino Acid d-Dicyclohexylalanine in the P3 Position. Implications on Oral Bioavailability and Antithrombotic EfficacyJournal of Medicinal Chemistry, 1997
- The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activityBioorganic & Medicinal Chemistry Letters, 1997
- An Improved Catalyst System for Aromatic Carbon−Nitrogen Bond Formation: The Possible Involvement of Bis(Phosphine) Palladium Complexes as Key IntermediatesJournal of the American Chemical Society, 1996
- A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline DerivativesJournal of Medicinal Chemistry, 1994